Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

Centre Scientifique de Monaco

Status: Unknown

Conditions: COVID-19; Vaccines; SARS-CoV-2; Antibody

Study type: Observational

Funder types: Other

Identifiers

NCT05084950

PRO_CSM_02_2021

Details and patient eligibility

About

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.

Full description

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Enrollment: 10,000 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participant must live in the Principality of Monaco
• Deliver a written consent to participate to the study
• And/Or Have been infected with SARS-CoV-2
• And/Or Have been, or are about to be, vaccinated against SARS-CoV-2

Exclusion criteria

• None of the above